NewAmsterdam Pharma N.V.

NASDAQ: NAMS · Real-Time Price · USD
25.06
-0.11 (-0.44%)
At close: Aug 15, 2025, 3:59 PM
25.07
0.04%
After-hours: Aug 15, 2025, 04:10 PM EDT

NewAmsterdam Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
45.56M 12.76M 95.91M n/a
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
45.56M 12.76M 95.91M n/a
Operating Income
-176.29M -165.73M -3.32M -30.73M
Interest Income
16.88M 10.22M 268.03K 361.1K
Pretax Income
-241.6M -160.25M -21.14M -36.71M
Net Income
-241.6M -176.94M -21.14M -36.71M
Selling & General & Admin
70.45M 29.77M 18.22M 5.27M
Research & Development
151.41M 159.42M 81.01M 25.46M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
221.85M 197.06M 116.78M 36.35M
Interest Expense
n/a 6.8M n/a n/a
Selling & Marketing Expenses
n/a 4.06M 1.6M 858.39K
Cost & Expenses
221.85M 183.23M 116.78M 36.35M
Income Tax Expense
-1K 27K n/a n/a
Shares Outstanding (Basic)
94.36M 82.16M 18.97M 17.75M
Shares Outstanding (Diluted)
94.36M 82.16M 18.97M 17.75M
EPS (Basic)
-2.56 -2.15 -1.11 -3.34
EPS (Diluted)
-2.56 -2.15 -1.11 -3.34
EBITDA
-241.49M -176.86M -3.31M -30.73M
EBIT
-241.6M -176.91M -22.35M -30.73M
Depreciation & Amortization
113K 49K 8.4K 4.39K